Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump administration.

The proposal would let patients get Wegovy, Ozempic and related drugs for obesity, which Medicare and Medicaid does not cover now.

Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid.